Overall, the proportion of patients with negative CEA was significantly higher than the proportion of patients with negative mSEPT9 at 6-months (71.8% vs 55.3%; P = 0.035) and 12-months (68.1% vs 48.1%; P = 0.028), especially for cases with non-advanced cancer (stage I/II) at 6-months (79.2% vs 55.6%; P = 0.013), and those without evidence of clinical recurrence at 6-months (72.9% vs 55.3%; P = 0.038) and 12-months (69.7% vs 49.0%; P = 0.033). The gene discussed is CEACAM5; the disease is cancer.